%20(1).webp)
Peptides for Migraines: What Causes Attacks and What Research Targets
Updated: Sep 7
A migraine can turn an ordinary day into hours of throbbing pain, nausea and sensitivity to light or sound. Finding useful migraine solutions starts with understanding why the nervous system becomes sensitive in the first place.
Interest in peptides for migraines centres on several connected questions: Can brain cells manage energy better? Can pain signals be reduced? Can inflammatory activity around nerves be controlled?
Different peptides address different research questions. SS-31 is studied for mitochondrial energy and headache-related pain. MOTS-C is linked to energy sensing. ARA-290 focuses on nerve protection, while BPC-157, thymosin beta-4, Semax and Selank are studied for repair or nervous-system signalling.
The studies below range from migraine trials to animal and cell experiments. Each section explains the setting and the finding so the connection to migraine is clear.
Why migraines happen
Migraine involves a nervous system that is unusually sensitive to certain changes. An attack can develop when several pressures overlap, rather than from one food, one chemical or one damaged structure.
Four areas help explain that sensitivity: the head’s pain pathways, cellular energy, inflammatory signalling and, in some people, histamine.
The trigeminal nerve and CGRP: how pain signals build
The trigeminal nerve carries sensation from much of the head and face. Its branches also supply tissues surrounding the brain. During migraine, this system can release CGRP, a peptide that helps transmit pain and affects blood vessels.
Researchers measured increased CGRP during spontaneous migraine attacks. In a separate controlled experiment, giving CGRP to migraine-prone participants triggered delayed migraine attacks in some of them. Together, these findings help explain why CGRP is an important treatment target. Goadsby et al., 1990 Lassen et al., 2002
One distinction matters: CGRP is itself a peptide involved in migraine. The seven peptides discussed below have different research targets; they should not be confused with medicines that specifically block CGRP.
Conceptual illustration of trigeminal nerve signalling and CGRP; not an anatomical map.
Mitochondria and ATP: the brain’s energy supply
Mitochondria turn fuel into ATP, the energy cells use to work. Brain cells need that energy to send signals, restore their electrical balance and respond to changing demands.
Imaging studies have found reduced energy reserves in some migraine groups. One found lower ATP and phosphocreatine, which helps buffer energy supply. Another linked altered brain energy metabolism with lower free magnesium. Reyngoudt et al., 2011 Lodi et al., 2001
This has led to a useful research idea: a susceptible brain may struggle when its workload exceeds its energy reserve. That helps explain the interest in mitochondrial support, including SS-31, riboflavin and CoQ10. It does not mean every migraine starts with the same energy problem. Gross et al., 2019
Mitochondria help supply the ATP that nerve cells use to maintain activity.
Neuroinflammation: why nerves can stay sensitive
Neuroinflammation means inflammatory signalling within or around the nervous system. Support cells and immune signals can influence how strongly pain pathways respond.
A PET/MRI study in people with migraine with aura found increased signal from a marker associated with glial activation. Glial cells support and regulate nerves; changes in their activity may help explain lingering sensitivity. Albrecht et al., 2019
Inflammation is therefore one part of the migraine picture, alongside nerve activity and energy supply.
Histamine and DAO: a possible trigger pathway
Histamine is a chemical messenger involved in immune responses and other body functions. In a controlled study, histamine triggered headache and delayed migraine through H1-receptor signalling. Lassen, Thomsen and Olesen, 1995
DAO, short for diamine oxidase, helps break down food-derived histamine in the intestine. Researchers have studied DAO supplementation specifically in people with episodic migraine and low DAO activity.
In that trial, attacks became shorter within the DAO group, but the difference between groups was not statistically significant. Attack frequency and pain intensity improved similarly in both groups. The practical takeaway is that histamine deserves attention when there is a consistent pattern, rather than being assumed to explain every migraine. Izquierdo-Casas et al., 2019
Seven peptides discussed in migraine research
1. SS-31: mitochondrial energy and headache sensitivity
SS-31, also called elamipretide, interacts with cardiolipin, a fat that helps maintain the inner membrane of mitochondria. That membrane houses much of the machinery used to produce ATP.
In an ischemia study, SS-31 helped preserve mitochondrial structure and supported energy recovery after blood flow returned. Birk et al., 2013
Its most direct headache connection comes from a 2023 mouse study. SS-31 reduced pain-related responses and improved mitochondrial function in a brainstem region that processes trigeminal signals. Researchers linked part of the effect to SIRT3 and PGC-1α, regulators involved in maintaining and building mitochondria. Shan et al., 2023
Why it attracts attention: this study connects an energy-targeting peptide with headache-related pain in the same experiment. Among the seven peptides here, SS-31 has the clearest direct headache-model evidence.
2. MOTS-C: how cells respond to energy stress
MOTS-C is a short peptide encoded by mitochondrial DNA. Its research focuses on how cells adjust when fuel availability and energy demands change.
One target is AMPK, which acts like a cellular fuel gauge. In cell and mouse experiments, MOTS-C affected this pathway and improved measures of insulin sensitivity and metabolic control. Lee et al., 2015
A later study showed that MOTS-C can move into the cell nucleus during metabolic stress and influence genes involved in the stress response. Kim et al., 2018
Its connection to migraine is the energy question: whether improving the way cells respond to metabolic stress could influence attack susceptibility. These papers establish metabolic mechanisms, rather than measuring migraine relief.
3. ARA-290: nerve protection and repair
ARA-290, also called cibinetide, is derived from erythropoietin and designed to activate tissue-protective signalling without stimulating red blood cell production.
In a rat model of inflammatory nerve disease, researchers reported less inflammatory nerve infiltration and improvements in nerve repair and remyelination—the rebuilding of the protective covering around nerves. Liu et al., 2014
Small clinical studies in sarcoidosis-related small-fibre neuropathy and diabetic neuropathy also reported improvements in selected nerve symptoms or measurements. These studies concern peripheral nerve disorders, which differ from migraine. Heij et al., 2012 Brines et al., 2015
Why it attracts attention: ARA-290 brings together inflammatory control and nerve protection, two relevant areas when studying pain.
4. BPC-157: blood-vessel and tissue-repair pathways
BPC-157 is studied mainly in injury and repair models. In endothelial-cell and animal experiments, it increased blood-vessel growth and supported blood-flow recovery through signalling involving VEGFR2. This receptor helps cells respond to signals for blood-vessel growth. Hsieh et al., 2017
A separate rat study of stomach injury reported reduced inflammation and cell stress alongside changes in repair signalling. Wu et al., 2020
Its place in the migraine discussion is indirect: researchers are interested in the relationship between nerves, inflammation and surrounding tissues. Blood-vessel repair in an injured limb or stomach is a different outcome from reducing migraine attacks.
5. TB-500 and thymosin beta-4: how cells move and repair tissue
TB-500 is often grouped with thymosin beta-4, but the names should not be treated as interchangeable. An analytical study identified TB-500 as an acetylated seven-amino-acid fragment of the larger thymosin beta-4 peptide. Esposito et al., 2012
Thymosin beta-4 research examines cell movement, blood-vessel formation and repair. Its actin-binding region helps influence the internal structure cells use to move. In a mouse heart-injury study, full-length thymosin beta-4 supported cell survival and repair through signals including integrin-linked kinase and Akt. Philp et al., 2003 Bock-Marquette et al., 2004
The relevant theme is tissue repair. These findings belong to the specific molecules and injury models studied, rather than showing a direct migraine effect.
6. Semax: signals involved in nerve adaptation
Semax is studied for its effects on nerve growth signals, including BDNF and NGF.
BDNF means brain-derived neurotrophic factor. NGF means nerve growth factor. Both help regulate how nerve cells survive, adapt and communicate.
Rat studies found that Semax altered BDNF, its receptor TrkB, and NGF-related gene activity. The response varied across tissues and over time. Dolotov et al., 2006 Shadrina et al., 2010
This places Semax in the area of neuroplasticity: the nervous system’s ability to change. Neuroplasticity includes many processes, so increasing a growth signal is not automatically the same as reducing headache.
7. Selank: GABA-related nervous-system signalling
Selank is studied for effects on neurotransmission, the way nerve cells communicate.
A rat study found changes in genes involved in GABA-related signalling after Selank administration. GABA is a major inhibitory messenger, meaning it helps restrain nerve activity. The researchers proposed that Selank could influence this signalling system. Volkova et al., 2016
Its relevance is the regulation of nervous-system activity. The measured result was gene expression in rat brain tissue, rather than a change in headache frequency.
Research targets discussed above. TB-500 and full-length thymosin beta-4 are distinct molecules.
Migraine support beyond peptides
Energy production and inflammatory signalling also help explain interest in several nutritional approaches. Unlike a general mechanism study, a migraine trial can measure outcomes such as headache days, attack duration and rescue-medication use.
Riboflavin: vitamin B2 and energy production
Riboflavin helps the body produce cofactors needed for cellular energy metabolism. In a three-month randomized trial of 55 migraine patients, it reduced attack frequency and headache days compared with placebo. Schoenen, Jacquy and Lenaerts, 1998
Magnesium: nerve activity and energy use
Magnesium participates in nerve signalling and the use of ATP. A randomized trial of 81 participants found that oral magnesium reduced attack frequency more than placebo. Digestive side effects occurred in some participants. The formulation studied was trimagnesium dicitrate; different magnesium products should not be assumed to have identical results. Peikert, Wilimzig and Köhne-Volland, 1996
CoQ10 and ubiquinol: supporting the energy chain
CoQ10 helps transfer electrons during mitochondrial ATP production. In a small randomized migraine trial, CoQ10 improved attack frequency, headache days and days with nausea by the third month. Ubiquinol is the reduced form of CoQ10, but the trial evaluated CoQ10 rather than comparing formulations. Sándor et al., 2005
PEA: pain and inflammatory signalling
Palmitoylethanolamide, usually shortened to PEA, is a naturally occurring lipid signalling molecule. It is not a peptide.
A 2024 randomized study evaluated PEA taken at migraine onset and reported improvements in selected pain outcomes and reduced rescue-medication use. Separate laboratory research linked its anti-inflammatory action to PPAR-alpha, a receptor involved in regulating inflammatory responses. Briskey et al., 2024 Lo Verme et al., 2005
How to think about migraine solutions
A useful migraine plan starts with the pattern of attacks, rather than the longest list of compounds.
Tracking headache days, sleep, meals and possible triggers can help distinguish a repeatable pattern from a coincidence. An approach aimed at energy metabolism addresses a different question from one aimed at stopping pain signals during an attack. The metabolic view of migraine helps explain why these questions can overlap. Gross et al., 2019
The research falls into three practical groups:
Direct headache research: SS-31 in a mouse headache model; riboflavin, magnesium, CoQ10 and PEA in migraine trials.
A specific subgroup: DAO supplementation in people with migraine and measured DAO deficiency.
Related biological pathways: MOTS-C, ARA-290, BPC-157, thymosin beta-4, Semax and Selank in metabolic, nerve or repair studies.
A combination should not be assumed to inherit the results of every individual study. Combining several compounds also makes it harder to identify which change helped or caused an unwanted effect. These pathways provide a way to understand the research, not a ready-made injection protocol.
Common questions about peptides for migraines
Which peptide has the closest connection to migraine research?
Among the seven covered here, SS-31 has the most direct headache-model connection. Its study measured pain-related responses and mitochondrial function together. That is a more specific connection than a study measuring repair in another organ.
Does BPC-157 target CGRP?
The BPC-157 papers cited here investigated blood-vessel signalling and tissue injury. They do not establish BPC-157 as a CGRP blocker.
Why are mitochondria discussed so often?
Brain cells need a reliable energy supply to manage electrical activity. Findings of altered energy metabolism in some migraine groups have made mitochondrial function an important research target.
Is every migraine related to histamine?
No. Histamine can trigger migraine, but the DAO trial studied a selected group with low DAO activity. That makes it a focused question for an individual’s pattern, not an explanation for all attacks.
Are all peptides doing the same thing?
No. Even within this article, the targets range from mitochondrial membranes and energy sensing to nerve growth signals and tissue repair. The word “peptide” describes a type of molecule, not a shared benefit.
What this research means
The strongest reason to study peptides for migraines is their ability to act on specific biological processes. SS-31 connects mitochondrial function with headache sensitivity in a dedicated model. Other peptides help researchers examine energy regulation, nerve protection and repair.
For readers, the useful question is simple: what did the study actually measure? Keeping that question in view makes it easier to distinguish an interesting mechanism from an improvement in migraine symptoms—and to understand where each compound fits.
Continue reading
References
Goadsby PJ, Edvinsson L, Ekman R. “Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.” Annals of Neurology. 1990. View on PubMed
Lassen LH, Haderslev PA, Jacobsen VB, et al. “CGRP may play a causative role in migraine.” Cephalalgia. 2002. View on PubMed
Albrecht DS, Mainero C, Ichijo E, et al. “Imaging of neuroinflammation in migraine with aura: A [11C]PBR28 PET/MRI study.” Neurology. 2019. View on PubMed
Reyngoudt H, Paemeleire K, Descamps B, De Deene Y, Achten E. “31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients.” Cephalalgia. 2011. View on PubMed
Lodi R, Iotti S, Cortelli P, et al. “Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache.” Brain Research Bulletin. 2001. View on PubMed
Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. “The metabolic face of migraine—from pathophysiology to treatment.” Nature Reviews Neurology. 2019. View on PubMed
Lassen LH, Thomsen LL, Olesen J. “Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine.” NeuroReport. 1995. View on PubMed
Izquierdo-Casas J, Comas-Basté O, Latorre-Moratalla ML, et al. “Diamine oxidase (DAO) supplement reduces headache in episodic migraine patients with DAO deficiency: A randomized double-blind trial.” Clinical Nutrition. 2019. View on PubMed
Schoenen J, Jacquy J, Lenaerts M. “Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial.” Neurology. 1998. View on PubMed
Peikert A, Wilimzig C, Köhne-Volland R. “Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study.” Cephalalgia. 1996. View on PubMed
Sándor PS, Di Clemente L, Coppola G, et al. “Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.” Neurology. 2005. View on PubMed
Briskey D, Skinner R, Smith C, Rao A. “Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants—A Double-Blind Randomised Controlled Study.” Pharmaceuticals. 2024. View on PubMed
Lo Verme J, Fu J, Astarita G, et al. “The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide.” Molecular Pharmacology. 2005. View on PubMed
Birk AV, Liu S, Soong Y, et al. “The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.” Journal of the American Society of Nephrology. 2013. View on PubMed
Shan Z, Wang Y, Qiu T, et al. “SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model via Sirt3/Pgc-1α positive feedback loop.” The Journal of Headache and Pain. 2023. View on PubMed
Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism. 2015. View on PubMed
Kim KH, Son JM, Benayoun BA, Lee C. “The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.” Cell Metabolism. 2018. View on PubMed
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Research. 2006. View on PubMed
Shadrina M, Kolomin T, Agapova T, et al. “Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action.” Journal of Molecular Neuroscience. 2010. View on PubMed
Volkova A, Shadrina M, Kolomin T, et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology. 2016. View on PubMed
Hsieh MJ, Liu HT, Wang CN, et al. “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.” Journal of Molecular Medicine. 2017. View on PubMed
Wu H, Wei M, Li N, et al. “Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157.” Drug Design, Development and Therapy. 2020. View on PubMed
Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. “Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.” Drug Testing and Analysis. 2012. View on PubMed
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. “The actin binding site on thymosin beta4 promotes angiogenesis.” FASEB Journal. 2003. View on PubMed
Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.” Nature. 2004. View on PubMed
Liu Y, Luo B, Han F, et al. “Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection.” PLOS ONE. 2014. View on PubMed
Heij L, Niesters M, Swartjes M, et al. “Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.” Molecular Medicine. 2012. View on PubMed
Brines M, Dunne AN, van Velzen M, et al. “ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.” Molecular Medicine. 2015. View on PubMed
